• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Will the monkeypox virus become more dangerous?
A few years ago, researchers scoured the remains of 1867 people who lived between 30,000 and 150 years ago for genetic traces of variola, the virus that causes smallpox. In the teeth and bones of four Northern Europeans from the Viking era, they found enough DNA to reconstruct entire variola genomes. The sequenced viruses weren’t direct ancestors of the feared variola strain that was eradicated in the second half of the 20th century. But they may hold a clue to how smallpox became so deadly. Over the span of 350 years, the Viking virus lost several genes , the researchers reported in a 2020 paper in Science...
Source: Science of Aging Knowledge Environment - September 15, 2022 Category: Geriatrics Source Type: research

News at a glance: New gene therapy, Europe ’s drought, and a black hole’s photon ring
ARCHAEOLOGY Drought exposes ‘Spanish Stonehenge’ for study Scientists are rushing to examine a 7000-year-old stone circle in central Spain that had been drowned by a reservoir for decades and was uncovered after the drought plaguing Europe lowered water levels. Nicknamed the “Spanish Stonehenge”—although 2000 years older than the U.K. stone circle—the Dolmen of Guadalperal (above) was described by archaeologists in the 1920s. The approximately 100 standing stones, up to 1.8 meters tall and arranged around an oval open space, were submerged in the Valdecañas reservoir after the construction of a ...
Source: Science of Aging Knowledge Environment - August 25, 2022 Category: Geriatrics Source Type: research

COVID-19 - guidance for management of children admitted to hospital and for treatment of non-hospitalised children at risk of severe disease, RCPCH
This best practice advice is focused on the management of confirmed or suspected SARS-CoV-2 infection in children admitted to hospital and on the currently available treatments for non-hospitalised children at risk of severe disease. This has been produced with the British Paediatric Allergy, Immunity and Infection Group. Last modified 4 March 2022
Source: Current Awareness Service for Health (CASH) - March 11, 2022 Category: Consumer Health News Source Type: news

COVID-19 - guidance for management of children admitted to hospital, RCPCH (updated 22nd October 2021)
This best practice advice is focused on the management of confirmed or suspected SARS-CoV-2 infection in children admitted to hospital. This has been produced with the British Paediatric Allergy, Immunity and Infection Group.
Source: Current Awareness Service for Health (CASH) - October 26, 2021 Category: Consumer Health News Source Type: news

Forewarned is Forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health
Br J Dermatol. 2021 May 20. doi: 10.1111/bjd.20495. Online ahead of print.ABSTRACTChronic spontaneous urticaria and angioedema (CSU/A) is a common condition with an estimated global point prevalence of 0.7% (95% C.I, 0.2-1.4)(1), higher in non-White populations. Symptoms present as an 'allergy mimic' but are underpinned by non-specific, non-IgE-mediated mast cell histamine release. The combination of common population prevalence and likelihood of vaccines precipitating symptoms in those with CSU/A presents an immediate risk to the SARS-COV-2 global vaccine program.PMID:34013621 | DOI:10.1111/bjd.20495
Source: The British Journal of Dermatology - May 20, 2021 Category: Dermatology Authors: W H Bermingham M R Ardern-Jones A P Huissoon M T Krishna Source Type: research

Johnson & Johnson Expands Phase 2a Clinical Trial of COVID-19 Vaccine Candidate to Include Adolescents
New Brunswick, NJ (April 2, 2021) – Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. “The COVID-19 pandemic has had a profound impact on adolescents, not just with the complications of the disease, but with their education, mental health, and wellbeing,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. “It is vital that we develop vaccines for everyone, everywher...
Source: Johnson and Johnson - April 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

PNR Weekly Digest: March 30, 2021
Items regarding COVID-19 information are indicated with an * In the Dragonfly: *NNLM Covid-19 Symposium. Keynote Speakers Announced. Registration is Open The Network of the National Library of Medicine (NNLM) is excited to announce a new, free virtual symposium focused on addressing the COVID-19 infodemic in our communities. The NNLM Virtual Symposium: Responding to the COVID-19 Infodemic is an opportunity to address misinformation and mistrust, raise awareness about the pandemic, and efforts to combat it. Symposium attendees can expect to come away from the 2-day experience with a better understanding of COVID-19 and shar...
Source: Dragonfly - March 30, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news

Can AstraZeneca ’s Vaccine Prevent the Spread of COVID-19 Virus?
In a new—yet to be peer-reviewed—study, the pharmaceutical company AstraZeneca and its partners at the University of Oxford report that their COVID-19 shot may not only protect against disease but also help to prevent spread of the SARS-CoV-2 virus. The news was heralded by policy makers desperate to see a vaccine that can curb spread of the disease, but scientists have been a bit more cautious. If confirmed, the results would represent a breakthrough in the COVID-19 vaccine race. So far, the shots authorized or approved around the world have shown strong protection against moderate to severe disease, but haven...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),1 continues to cause morbidity and mortality across the world. The expert recommendation is to continue biologic therapy unchanged in severe eosinophilic asthma2,3 but concern has been expressed as eosinopenia may be a risk factor for worse disease outcomes.4,5 Here, we report the outcomes of 4 patients from centers in the United Kingdom, Italy, and North America with COVID-19, while receiving treatment with mepolizumab, an anti –interleukin 5 monoclonal antibody, which reduces eosinophils to within the reference range.
Source: Annals of Allergy, Asthma and Immunology - January 12, 2021 Category: Allergy & Immunology Authors: Adnan Azim, Laura Pini, Zeeshan Khakwani, Santosh Kumar, Peter Howarth Tags: Letters Source Type: research

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience.
Capsule summary: This large case series of outcomes following COVID-19 demonstrates that, in comparison to the general population, adults with primary and secondary immunodeficiencies are at increased risk of morbidity and mortality following SARS-CoV-2 infection.
Source: Journal of Allergy and Clinical Immunology - December 14, 2020 Category: Allergy & Immunology Authors: Adrian M. Shields, Siobhan O. Burns, Sinisa Savic, Alex G. Richter, UK PIN COVID-19 consortium Source Type: research

COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience
As of November 2020, severe acute respiratory syndrome coronavirus 2 has resulted in 55 million infections worldwide and more than 1.3 million deaths from coronavirus disease 2019 (COVID-19). Outcomes following severe acute respiratory syndrome coronavirus 2 infection in individuals with primary immunodeficiency (PID) or symptomatic secondary immunodeficiency (SID) remain uncertain.
Source: Journal of Allergy and Clinical Immunology - December 14, 2020 Category: Allergy & Immunology Authors: Adrian M. Shields, Siobhan O. Burns, Sinisa Savic, Alex G. Richter, UK PIN COVID-19 Consortium Tags: Brief report Source Type: research

The Covid Pandemic: Broadening the Discourse
Thailand’s COVID-19 response an example of resilience and solidarity: a UN Resident Coordinator’s BlogBy Asoka BandarageCOLOMBO, Sri Lanka, Nov 10 2020 (IPS) SARS-CoV-2, the corona virus that causes COVID-19, has been spreading exponentially across the world over the last ten or so months. As of November 6th, according to the Center for Systems Science at Johns Hopkins University, there have been 49,195,581 cases of COVID-19, including 1,241,031 deaths. More than a third of the global population has been placed on lockdown. The global economy is experiencing the deepest global recession since World War 2 and massive n...
Source: IPS Inter Press Service - Health - November 10, 2020 Category: International Medicine & Public Health Authors: Asoka Bandarage Tags: Featured Global Headlines Health Human Rights Humanitarian Emergencies Peace TerraViva United Nations Source Type: news

Pages: 1  2